The average of price targets set by Wall Street analysts indicates a potential upside of 43.1% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the ...

Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

10x Genomics (TXG) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

The average of price targets set by Wall Street analysts indicates a potential upside of 55.9% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the ...

Wall Street expects a year-over-year increase in earnings on lower revenues when 10x Genomics (TXG) reports results for the quarter ended March 2025. While this widely-known consensus outlook is ...

Gene sequencing technology company 10x Genomics (NASDAQ: TXG) hasn't been having it easy in the past few days on the stock ...

Ladies and gentlemen, thank you so much for standing by and welcome to 10x Genomics First Quarter 2025 Earnings Conference Call. Please note that this call is being recorded. After speakers ...

Travel agency manager Hafizul Hawari applied for a plea bargain at the Sessions Court in Sepang, Selangor, on Monday (May 19) ...

While Pacific Biosciences' earnings were beat, shrinking sales, high debt, and poor macro environment do not inspire ...

Announces that an amendment to the Company's restricted share unit plan will be included in the matters to be presented to shareholders at the annual and special meeting of shareholders of Torex ...